Market capitalization | $34.80m |
Enterprise Value | $53.20m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.19 |
P/S ratio (TTM) P/S ratio | 3.39 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 0.44% |
Revenue (TTM) Revenue | $10.26m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
5 Analysts have issued a Curis, Inc. forecast:
5 Analysts have issued a Curis, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 10 10 |
0%
0%
|
|
Gross Profit | 9.52 9.52 |
9%
9%
|
|
EBITDA | -47 -47 |
5%
5%
|
EBIT (Operating Income) EBIT | -48 -48 |
3%
3%
|
Net Profit | -45 -45 |
3%
3%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Head office | United States |
CEO | James Dentzer |
Employees | 49 |
Founded | 2000 |
Website | www.curis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.